ACM
PRCT icon

Archon Capital Management’s Procept Biorobotics PRCT Stock Holding History

Archon Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$315K – 59
2025
Q4 		$315K Buy
+10,000
New +$332K 0.18% 45

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Archon Capital Management's PRCT Position: Q1 2026 in Review

Archon Capital Management sold out of Procept Biorobotics (PRCT) in Q1 2026, closing a stake of 10,000 shares — an estimated $315K sold.

Archon Capital Management first reported a position in PRCT in Q4 2025 and held it in 1 quarter. The position peaked at $315K in Q4 2025. 257 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

  • Archon Capital Management reported no remaining Procept Biorobotics position as of Q1 2026 after selling out during the quarter.
  • Archon Capital Management sold 10,000 Procept Biorobotics shares in Q1 2026, an estimated $315K.
  • Archon Capital Management first reported a position in Procept Biorobotics in Q4 2025 and held it in 1 quarter.
  • Archon Capital Management's Procept Biorobotics position peaked at $315K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Archon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.